NOV 24, 2021 11:00 AM PST

A prescription digital therapeutic to treat alcohol use disorders

WRITTEN BY: J. Bryce Ortiz

Can a software application be used treat alcohol use disorders? The medical technology company Pear Therapeutics is leading the way in showing that digital therapeutics are effective in treating substance use disorders. Early this week, the company announced that it received Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for its prescription digital therapeutic called reSET-A. The Breakthrough Device Designation allows the company to work closely with the FDA to more quickly and efficiently receive full approval for their product. 

The reSET-A therapeutic is a software-based disease treatment that is designed to directly treat alcohol use disorder. Alcohol use disorder is a common substance abuse disorder that is characterized by inability to control alcohol use despite severe social, occupational, and health consequences. Alcohol use disorder is common in the United States and affects nearly 14.1 million adults aged 18 and older. 

While treatments exist for alcohol use disorder, only about 1 in 10 individuals with the disease seek treatment. However, Pear Therapeutics hopes that their software will reach many individuals with the disorder to effectively treat it. Pear Therapeutic’s Chief Medical Officer, Yuri Maricich, said, “we believe [prescription digital therapeutics] can bring effective, evidence-based treatments for alcohol use disorder (AUD) to many more people, and in doing so help address the public health burden of AUD.”

The software works by supplying the patient with cognitive behavioral therapy via a phone-based application. The software also includes an associated dashboard for the prescribing clinician that displays information about the patients’ use of the reSET-A. The digital therapeutic is meant to be used in conjunction with other pharmacological treatments. 

This is the third prescription digital therapeutic product in Pear Therapeutic’s portfolio. The other two, reSET-O and reSET, are used to treat opioid abuse and substance abuse disorder, respectively. These programs have been evaluated in clinical research studies and have shown that these prescription digital therapeutics improve patient outcomes and save money. One study found that reSET-O was associated with fewer inpatient and emergency department encounters. Additionally, another study found reSET-O was a cost-effective treatment that helped increase sobriety adherence. Pear Therapeutics hopes to gain full FDA approval for reSET-A within the next year. 

 

Sources: Pear TherapeuticsNational Institute on Alcohol Abuse and AlcoholismPear TherapeuticsExpert Review of Pharmacoeconomics and Outcomes ResearchJournal of Medical Economics

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
OCT 05, 2021
Drug Discovery & Development
Drug repurposing for COVID-19
OCT 05, 2021
Drug repurposing for COVID-19
The coronavirus disease that began in 2019 (COVID-19) has infected nearly 235 million individuals and led to t ...
OCT 15, 2021
Drug Discovery & Development
Oxytocin Therapy Shows No Benefit for Autistic Children
OCT 15, 2021
Oxytocin Therapy Shows No Benefit for Autistic Children
Intranasal oxytocin therapy does not benefit autistic children and adolescents. The corresponding study was published in ...
OCT 25, 2021
Health & Medicine
Latest Cannabis Extraction Developments
OCT 25, 2021
Latest Cannabis Extraction Developments
In response to the growing demand for concentrates, cannabis product manufacturers are exploring new technological advan ...
NOV 19, 2021
Genetics & Genomics
Transcriptomics Method Can Reveal Genes Behind Venom Production
NOV 19, 2021
Transcriptomics Method Can Reveal Genes Behind Venom Production
Some of our best medications have come from nature. For years, researchers have been studying the properties of differen ...
NOV 19, 2021
Health & Medicine
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
NOV 19, 2021
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
A recent study by Columbia University and Weill Cornell Medicine researchers found that cannabis use disorder (CUD) in p ...
DEC 02, 2021
Microbiology
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
DEC 02, 2021
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
Crimean-Congo hemorrhagic fever (CCHF) is a deadly disease, which is fatal in about 30 percent of cases. It's caused ...
Loading Comments...